Kyung Dong Pharmaceutical Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Kyung Dong Pharmaceutical zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 43.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kyung Dong Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 162,674 | -20,708 | -7,999 | -32 | N/A |
| 9/30/2023 | 165,709 | 6,824 | -19,276 | -3,621 | N/A |
| 6/30/2023 | 174,143 | 8,710 | -19,746 | -5,156 | N/A |
| 3/31/2023 | 173,109 | 8,422 | -17,519 | -3,882 | N/A |
| 12/31/2022 | 182,718 | 12,161 | -11,487 | -1,075 | N/A |
| 9/30/2022 | 181,798 | 6,506 | 5,863 | 8,711 | N/A |
| 6/30/2022 | 183,683 | 9,179 | 7,491 | 9,704 | N/A |
| 3/31/2022 | 185,793 | 12,291 | 8,962 | 11,526 | N/A |
| 12/31/2021 | 177,611 | 12,672 | 7,685 | 12,422 | N/A |
| 9/30/2021 | 175,894 | 13,577 | -19,991 | 4,049 | N/A |
| 6/30/2021 | 172,332 | 11,669 | -14,292 | 9,512 | N/A |
| 3/31/2021 | 171,853 | 11,087 | -21,738 | 6,344 | N/A |
| 12/31/2020 | 173,828 | 12,459 | -11,244 | 17,116 | N/A |
| 9/30/2020 | 175,091 | 12,916 | 11,632 | 18,460 | N/A |
| 6/30/2020 | 174,263 | 18,549 | 3,061 | 9,961 | N/A |
| 3/31/2020 | 176,348 | 20,788 | 11,073 | 13,359 | N/A |
| 12/31/2019 | 176,500 | 20,126 | -4,196 | -2,781 | N/A |
| 9/30/2019 | 175,906 | 5,751 | -189 | 2,050 | N/A |
| 6/30/2019 | 177,842 | 3,155 | 9,615 | 12,950 | N/A |
| 3/31/2019 | 175,602 | 3,193 | 12,191 | 15,589 | N/A |
| 12/31/2018 | 179,316 | 5,242 | 29,504 | 33,268 | N/A |
| 9/30/2018 | 180,112 | 16,912 | 28,150 | 33,220 | N/A |
| 6/30/2018 | 181,528 | 18,700 | 24,865 | 28,864 | N/A |
| 3/31/2018 | 181,861 | 20,562 | 22,976 | 27,990 | N/A |
| 12/31/2017 | 177,772 | 20,477 | 9,044 | 14,788 | N/A |
| 9/30/2017 | 173,022 | 22,222 | N/A | 19,863 | N/A |
| 6/30/2017 | 166,640 | 19,444 | N/A | 19,176 | N/A |
| 3/31/2017 | 162,703 | 18,670 | N/A | 18,588 | N/A |
| 12/31/2016 | 158,599 | 17,609 | N/A | 25,628 | N/A |
| 9/30/2016 | 155,705 | 18,629 | N/A | 24,324 | N/A |
| 6/30/2016 | 153,079 | 13,673 | N/A | 23,802 | N/A |
| 3/31/2016 | 150,793 | 13,928 | N/A | 21,205 | N/A |
| 12/31/2015 | 151,893 | 14,132 | N/A | 18,257 | N/A |
| 9/30/2015 | 153,195 | 15,395 | N/A | 15,456 | N/A |
| 6/30/2015 | 151,288 | 22,404 | N/A | 17,088 | N/A |
| 3/31/2015 | 153,286 | 22,924 | N/A | 20,430 | N/A |
| 12/31/2014 | 153,260 | 24,518 | N/A | 23,130 | N/A |
| 9/30/2014 | 151,581 | 23,891 | N/A | 25,401 | N/A |
| 6/30/2014 | 148,236 | 25,787 | N/A | 22,025 | N/A |
| 3/31/2014 | 140,863 | 24,591 | N/A | 15,381 | N/A |
| 12/31/2013 | 133,074 | 18,852 | N/A | 16,423 | N/A |
| 9/30/2013 | 124,156 | 6,156 | N/A | 17,152 | N/A |
| 6/30/2013 | 125,073 | 2,654 | N/A | 14,406 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von A011040 über der Sparquote liegt (2.3%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von A011040 schneller wachsen werden als der Markt KR
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von A011040 in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von A011040 schneller wachsen werden als der Markt von KR.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von A011040 schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von A011040 in 3 Jahren voraussichtlich hoch sein wird